Skip to main content
Amylyx Pharmaceuticals, Inc. logo

Amylyx Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · AMLX ISIN · US0321085088 US Manufacturing
Open in API
Filings indexed 384 across all filing types
Latest filing 2022-01-21 Major Shareholding Noti…
Country US United States of America
Listing US AMLX

About Amylyx Pharmaceuticals, Inc.

https://www.amylyx.com/

Amylyx Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery and development of novel therapies for neurodegenerative diseases and other conditions with high unmet medical needs. The company's primary therapeutic candidate was AMX0035 for the treatment of amyotrophic lateral sclerosis (ALS). In April 2024, following the results of a Phase 3 clinical trial, Amylyx announced it would voluntarily withdraw the marketing authorizations for AMX0035 in the U.S. and Canada. The company is advancing a pipeline of other investigational therapies, utilizing a modality-agnostic approach to match treatments to diseases based on mechanistic rationale and rigorous scientific data.

Recent filings

Filing Released Lang Actions
SC 13G
Major Shareholding Notification
2022-01-21 English
FORM 4
Director's Dealing
2022-01-14 English
S-8
Share Issue/Capital Change Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC, which is used to register securities to be offered under employee benefit plans such as stock option plans and employee stock purchase plans. It includes detailed information about the plans, the number of shares to be registered, and legal provisions related to indemnification of directors and officers. This type of filing is related to share issuance and capital changes under employee plans, not a financial report, management change, or other categories. Therefore, the appropriate classification is Share Issue/Capital Change (SHA). The document length and content confirm it is the registration statement itself, not just an announcement or certification.
2022-01-12 English
FORM 3
Director's Dealing
2022-01-12 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content focuses on amendments to the company's articles of incorporation and bylaws, specifically related to the IPO and corporate governance changes. There are no financial statements or detailed financial performance data included. The document is not an annual or quarterly report, nor is it an earnings release or audit report. It is also not a proxy statement or voting results announcement. The primary purpose is to disclose corporate governance changes and legal amendments. Therefore, the most appropriate classification is Regulatory Filings (RNS), which covers miscellaneous regulatory announcements that do not fit other categories.
2022-01-11 English
FORM 4 SUBMISSION
Director's Dealing
2022-01-11 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.